Cervical cancer is attributable to continuous expression of the E6 and E7 oncoproteins of the high-risk human papillomaviruses. These proteins target p53 and members of the retinoblastoma cellular regulatory protein family respectively for degradation, disrupting cellular control over apoptosis, senescence and the cell cycle. Delivery of short interfering RNAs (siRNAs) targeting mRNA from the HPV16 E6/E7 open reading frame to HPV16-positive cell lines, led to an 80% reduction in full-length transcripts and 60% reduction in total (full-length and spliced) transcripts. Downregulation of E6 mRNA led to increased levels of p53 detectable by western blot and resulted in an eightfold increase in luciferase expression from a p53-responsive reporter plasmid. Downregulation of E7 mRNA reduced the levels of E7 protein and increased the levels of hypophosphorylated pRb. Cellular proliferation was reduced after siRNA delivery; the effect being greater in SiHa cells than CaSki cells and when full-length transcripts encoding E6 and spliced transcripts encoding E7 were both targeted. There was no loss of proliferation in human papillomavirus-negative cell lines. Elevation of p53 in the absence of changes to Rb led to 35% of CaSki cells undergoing apoptosis, whereas in SiHa cells restoration of both p53 and hypophosphorylated Rb had the greatest effect with 25% of cells undergoing apoptosis. The combined use of oncogene-targeting siRNA with either carboplatin, irinotecan, leptomycin B or doxorubicin led to additive toxicity, whereas, with cisplatin, led to sub-additive toxicity. In contrast, siRNA combined with paclitaxel treatment resulted in synergistic toxicity, with intronic siRNA (which mainly targets E6) more effective than exonic siRNA (which targets both E6 and E7). The growth of SiHa xenograft tumors was reduced using paclitaxel combined with intronic and exonic siRNA, compared with exonic siRNA alone, confirming the synergistic relationship between p53 restoration and paclitaxel.
Introduction
Cervical cancer screening has significantly reduced mortality rates in the United Kingdom since its introduction in 1964. However, there are still 2800 new cases diagnosed each year leading to around 950 deaths. 1 Virtually all precursor cervical dysplasia and cancers result from persistent infection with high-risk subtype human papillomaviruses (HPVs). [2] [3] [4] [5] [6] HPVs are nonenveloped small double-stranded DNA viruses separated into low-and high-risk categories on the basis of their transforming properties. A small subgroup of high-risk types (HPV16, 18, 31, 33 and 45) have been identified in over 90% of cervical cancers. 7 The recent development of two prophylactic vaccines consisting of virus-like particles that expose the immune system to viral L1 surface antigens from HPV6, 11, 16 and 18 in the case of Gardasil (Merck & Co., Inc, Whitehouse Station, NJ), and HPV16 and 18 in the case of Cervavix (GSK, Uxbridge, UK), is expected to significantly reduce the incidence of HPV infections. [8] [9] [10] However, in preinfected individuals transformed cells lose L1 expression; therefore, the vaccine is unlikely to improve responses to tumors. Furthermore, the vaccine is recommended for adolescent women before sexual activity with some communities resistant to its introduction on the basis that it will provide an excuse for promiscuity, suggesting uptake may not be comprehensive. 11 Consequently, improved therapies for cervical cancer are still required.
Human papillomaviruses lack the DNA and RNA polymerases required for their life cycle and therefore coopt cellular replicative proteins by driving the cell into a proliferating state. The transforming activity of high-risk HPV types is dependent on the functions of viral E6 and E7 oncogenes, continuous E6/E7 expression being required to maintain the transformed phenotype. 12 HPV E7 interacts with cell cycle regulatory proteins, including the 'pocket protein' family of retinoblastoma protein (Rb) 13, 14 p107 and p130, 15, 16 and cyclin-dependent kinase inhibitors (CKIs), p21 WAF1/CIP117,18 and p27
KIP1
, 19 thus upregulating genes required for G1/S transition and DNA synthesis. pRb becomes dephosphorylated when cells enter the late M phase, hypophosphorylated pRb being the active form that inhibits S phase entry. The E7 oncoprotein forms complexes with hypophosphorylated pRb, destabilizing and promoting its proteolysis, allowing cellular entry into the S-phase. The host cell response is to activate the p53 tumor suppressor, leading to senescence or apoptosis. However, HPV E6 forms a complex with E6-associated protein ligase and the tumor suppressor p53, mediating p53 ubiquitination and proteosomal degradation. 20, 21 In the absence of p53, cell cycle arrest in response to genetic insult is abolished, allowing accumulation of harmful mutations that contribute to malignant progression. Consequently, although HPV E6 and E7 can immortalize cells independently, their cooperative effects enhance immortalization efficiency. As the p53 and Rb genes usually remain intact in cervical cancer, strategies that target viral oncoproteins are good candidates for genetic therapies.
The E6 and E7 oncoproteins of HPV16 and HPV18 are transcribed as a single bicistronic mRNA using a common promoter and early polyadenylation site. 22 For HPV 16, a number of alternative splice events generate a complex pattern of mRNAs termed E6* I-III (Figure 1) , with E6* I more abundant than the unspliced full-length transcript. [25] [26] [27] [28] [29] For HPV18 the splicing pattern of the E6E7 pre-mRNA is simpler with a single 3 0 acceptor splice site generating a uniformly sized intron 1. There are conflicting reports as to whether the HPV16 E7 protein is translated more efficiently from the spliced E6* I transcript 29 or with equal efficiency from spliced and full-length transcripts. 30 Short interfering RNA (siRNA) technology can generate specific silencing of target mRNA in mammalian cells. 31 To silence HPV E6/E7 oncogenes, two strategies have been adopted. First, using siRNA sequences which recognize intronic targets that degrade only full-length transcripts. As E6 can only be translated from the full-length transcript, whereas E7 can be generated from the spliced versions, 'intronic' siRNAs will inhibit production of E6 more than E7. Second, siRNAs that target exons (exonic) degrade both full-length and spliced transcripts, thus downregulating both E6 and E7. Studies using intronic and exonic siRNAs designed to target HPV16 or 18 E6/E7 sequences have shown increased levels of p53 [32] [33] [34] [35] [36] [37] [38] [39] [40] and hypophosphorylated pRb, 32, 34, 35, 39 after the delivery to HPV-containing cervical cell lines (Figure 1 and Table 1a ). Each study showed attenuated cell growth; however, there were conflicting results regarding whether the outcome was the induction of apoptosis 32, 34, 38, 40 or cellular senescence. 33, 37 In either case, the effects of the treatment, although providing proof of principle, were unlikely to be powerful enough to achieve clinical benefit.
We have examined the combined effects of chemotherapy drugs with siRNA targeting E6 alone or in combination with E7 in HPV16-positive cell lines. After p53 restoration with both intronic and exonic siRNA, we observed synergistic cytotoxicity when siRNAs were combined with paclitaxel, downregulation of E6 alone generating the greatest benefit. Using human cervical cell xenografts subcutaneously implanted into nude mice, we have examined for the first time the effect of combined systemic administration of paclitaxel with intratumoral injections of siRNA. Tumor growth was attenuated to a greater degree using intronic and exonic siRNA in combination with paclitaxel, rather than exonic siRNA alone with paclitaxel. This would indicate that in the presence of this cytotoxic agent, there was an advantage in restoring p53 activity by E6 downregulation without degrading E7.
Materials and methods

Cell lines
CaSki human cervical epithelial carcinoma cells containing B600 copies of the HPV16 genome were maintained in RPMI 1640 medium (PAA Laboratories GmbH, Yeovil, UK) supplemented with 10% fetal calf serum (FCS) (PAA), 10 mM N- Quantitative reverse transcription PCR for detection of viral mRNA
The levels of HPV16 E6/E7 mRNA were determined by two-stage quantitative reverse transcription PCR. Total RNA was isolated from transfected cells using the RNeasy kit (Qiagen) incorporating a genomic DNA elimination step, according to the manufacturer's instructions. cDNA was generated from 500 ng of total RNA using a blend of oligo-dT and random primers, and the Omniscript kit (Qiagen) according to the manufacturer's instructions. Negative controls were generated using reactions lacking reverse transcriptase enzyme. cDNA samples were analyzed by quantitative PCR using TaqMan Gold polymerase, (Applied Biosystems, Warrington, UK); full-length E6/E7 transcripts detected using forward Abbreviation: siRNA, short interfering RNA. 0 -CAAGCTTCCCGTTCTCAGCC-3 0 . Each reaction was carried out using an ABI Prism 7000 thermal cycler (Applied Biosystems) consisting of 50 1C for 2 min, 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. The levels of HPV16 E6/E7 mRNA were normalized using glyceraldehyde 3-phosphate dehydrogenase mRNA after the confirmation that the amplification efficiencies of the two genes were comparable (DC T o0.1).
Detection of viral and host cell proteins by western blotting After siRNA delivery, the levels of p53 in nuclear cell lysates, and HPV16 E7 and pRb in whole cell lysates were determined by western blot. Cells were lysed using M-PER (whole cell) or N-PER (nuclear) buffer (Peirce Biotechnology, Rockford, IL) containing complete protease inhibitor cocktail tablets (Roche, Welwyn Garden City, UK) for 30 min on ice and spun at 13k r.p.m. for 20 min at 4 1C in a minicentrifuge. The protein concentration in each lysate was determined using the colorimetric Advanced protein assay kit (Cytoskeleton, Denver, CO). 25-80 mg of sample protein was incubated with 3 Â protein loading buffer at 95 1C for 5 min, and separated on a 12% (p53), or a 10%/20% gradient (E7 and pRb) SDS-polyacrylamide gel electrophoresis. Proteins were transferred to PVDF membranes and blocked for 90 min at room temperature in Tris buffered saline containing 0.1% Tween-20 and 5% non-fat milk. Primary antibodies against p53 (DO-1, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:1000, HPV16 E7 (ED-17, Santa Cruz Biotechnology) diluted 1:500 or pRb (G3-254, BD Pharmingen, Plymouth, UK) diluted 1:1000 were then added for 16 h at 4 1C in the case of p53 and pRb, and for 40 h for E7. HRP-conjugated goat anti-mouse secondary antibodies (Sigma Aldrich, Gillingham, UK) diluted 1:2000 were added for 90 min at room temperature, and detected using the LumiGLO chemiluminescence substrate system (KPL, Gaithersburg, MD). Each blot was stripped and re-probed with anti-GAPDH (ab9484, Abcam, Cambridge, UK) antibodies diluted 1:5000 as a protein loading control.
Functional p53 reporter assay
The p53 luciferase reporter vector containing a luciferase gene downstream of multiple p53 transcription factor binding sites (Panomics, Fremont, CA), or empty control vector, were transfected into cells to assess p53 biological activity after E6/E7 downregulation. Each experiment was carried out using 5 Â 10 4 cells seeded into a 24-well plate 24 h before the addition of plasmid DNA. Plasmid DNA and siRNA was complexed with DOTAP (Roche) according to the manufacturer's instructions. Complexes were added to cells such that each well received 0.2 mg plasmid DNA with or without 100 nM siRNA in serumfree medium for 4 h. Complete (10% FCS) medium was then added, and cells were incubated for a further 48 h. Cells were lysed with Promega lysis buffer, and the luciferase activity was determined using the Promega luciferase assay kit and a Lumat LB9507 luminometer (Berthold Technologies, Harpenden, UK), standardized for protein content.
Apoptosis assay
The degree of cellular apoptosis mediated by treatment with siRNA targeting HPV16 E6/E7 was determined using Annexin-V-Fluos (Roche). A total of 5 Â 10 5 cells were cultured in a 6-well plate for 24 h. After siRNA delivery, the cells were cultured for a further 72 h. Floating cells were collected and pooled with adherent cells detached from the plate by trypsinization. The cells were then pelleted and resuspended in 100 ml of Annexin-V-FLUOS labeling reagent for 15 min at room temperature. The percentage of positively stained cells was then determined by flow cytometry.
Chemotherapy assays
A total of 4 Â 10 3 CaSki or SiHa cells and 5 Â 10 3 C33-A cells were seeded into 96-well plates 24 h before the addition of siRNA. E6/E7-Intron, E6/E7-Ex2 or NS siRNA were complexed with oligofectamine according to the manufacturer's instructions. Complexes were then added to cells in serum-free medium such that each well received 30 nM siRNA. Complexes were incubated for 4 h, and the medium was replaced with 10% serum-containing medium for 24 h. Cytotoxic agents were then added at the indicated concentration, and cells were incubated for 4 d. The number of cells was determined using the CellTiter 96AQ UEOUS reagent (Promega) as described above.
Animal studies
In all, 3.2 Â 10 6 SiHa cells were implanted subcutaneously into the flanks of 6-8-week-old female MF-1 nude mice, and tumors were allowed to develop to 34-268 mm 3 in volume. Mice were randomly divided into five groups (n ¼ 4 or 5) to receive (1) mock, (2) paclitaxel only, (3) paclitaxel þ siNS, (4) paclitaxel þ exonic siRNA (E6/ E7-Ex2) or (5) paclitaxel þ exonic (E6/E7-Ex2) and intronic (E6/E7-Intron) siRNA. Paclitaxel (SigmaAldrich, Gillingham, UK) was resuspended at 20 mg ml -1 in 50% ethanol/50% Cremophor EL (Sigma) and diluted to 2 mg ml -1 using 5% dextrose. siRNA was complexed with oligofectamine as described above. On day 1 and day 4, 100 ml of vehicle or 2 mg ml -1 paclitaxel (10 mg kg -1 ) was injected into the tail vein of each mouse. Fifty ml of siRNA complexes or vehicle were injected intratumorally into two sites (25 ml in each) such that each mouse received 2 mg of siRNA. Tumor volume was measured every two to three days until tumors reached 905 mm 3 , and mice were euthanized.
Results
Targeting oncogenic E6 and E7 mRNA using intronic and exonic short interfering RNA To reduce HPV16 E6 and E7 expression, siRNA sequences were designed targeting either an intron or exons within the E6/E7 pre-mRNA (Figure 1, Table 1b ). The ability of the siRNAs to degrade target mRNA were tested using CaSki cells containing B600 copies of the HPV16 genome. After siRNA delivery, the level of E6 mRNA was determined by quantitative reverse transcription PCR using primers that specifically detect full-length transcripts, whereas the level of E7 mRNA was determined using primers that detect both full-length and spliced transcripts. Introduction of intronic siRNA (E6/ E7-Intron) led to an 80% reduction in E6 mRNA (fulllength transcripts) ( Figure 2 ). Levels of E7 mRNA were reduced by around 30%, probably because of the sevenfold excess of spliced transcripts present in the cell, 39 for which the intronic siRNA has no target. Introduction of the exonic siRNA (E6/E7-Ex2) also led to a loss of E6 mRNA, although the reduction was smaller than with intronic siRNA, possibly because of the larger number of target transcripts, both spliced and full length, present in the cell. As expected, the exonic siRNA generated an equal reduction in E6 and E7 mRNA, as it degrades all the E6/E7 transcripts. The combined use of intronic and exonic siRNA in equal concentration, reduced target mRNA to levels intermediate between those generated with either alone. There was no effect on E6 mRNA using control siRNA, although there was a small loss of E7 mRNA, suggesting that this sequence confers some degree of non-specific downregulation of spliced transcripts.
Experiments in SiHa cells containing 1-2 copies of the HPV16 genome were similar, however, the percentage reduction of E6 mRNA by E6/E7-Intron siRNA was lower (data not shown). Even though there are fewer genome copies in SiHa cells than CaSki cells, and correspondingly fewer total E6/E7 transcripts, the splicing of the pre-mRNA is less efficient in SiHa cells; thus, the overall level of full-length transcripts between cell types is similar. 39 In addition, the transfection of SiHa cells is marginally less efficient than CaSki cells (data not shown).
Elevation of p53 using short interfering RNA targeting E6
The lack of an effective antibody against HPV16 E6 means that siRNA effects on protein expression cannot be directly observed. However, a reduction of E6 would be expected to lead to increased levels of p53 because of reduced E6-mediated degradation. Levels of p53 were initially assessed by western blotting CaSki cell nuclear extracts, using an anti-p53 antibody. After 24 h, cells treated with either intronic or exonic siRNA showed large increases in levels of p53 compared with mock or control siRNA-treated cells (Figure 3a) , consistent with successful E6 silencing.
To determine whether induced p53 was functionally active, cells were transfected with a luciferase reporter plasmid driven by p53-response elements. HPV-negative C33-A cells that received p53 reporter plasmid, gave high levels of luciferase expression after 48 h, indicative of functional p53 ( Figure 3b) ; co-transfection of E6/E7-Intron siRNA having no effect because of the lack of HPV target mRNA in these cells. In contrast, SiHa and CaSki cells receiving plasmid alone, did not express luciferase because of the continued presence of E6 degrading p53 (Figures 3c and d) . However, co-delivery of E6/E7-Intron siRNA with p53 reporter plasmid led to high levels of luciferase expression, indicative of functional p53 accumulation. Luciferase activity was not present at 24 h but was induced by 38 h, indicative of siRNA degrading E6/E7 full-length mRNA transcripts, a reduction in E6 protein and consequent rises in p53, leading to transcription of the luciferase reporter gene (Figure 3c ). Co-delivery of E6/E7-Ex2 siRNA with p53 reporter plasmid also generated luciferase expression albeit at reduced amounts. The combined use of intronic and exonic siRNA with p53 reporter plasmid gave lower activity than either siRNA alone. There was virtually no expression from cells co-transfected with p53 reporter plasmid, and either control siRNA against EGFP or nonspecific siRNA. CaSki and SiHa cells co-transfected with E6/E7-Intron siRNA and a control plasmid lacking p53-response elements showed no luciferase expression (Figure 3d, black bars) . . In all, 100 nM siRNA was added to 10 5 cells, and target mRNA levels were determined by qRT-PCR after 12 h. Levels of E6 mRNA were determined using primers that detect full-length transcripts only (white bars), and E7 mRNA were determined using primers that detect both full-length and spliced transcripts (black bars).
Elevation of hypophosphorylated Rb using short interfering RNA targeting E7 To assess the effects of intronic and exonic siRNA on E7 protein levels, CaSki cells were treated with siRNA and examined after 24 h by western blot using an anti-HPV16 E7 antibody. The levels of E7 protein were reduced after the delivery of E6/E7-Ex2, however E6/E7-Ex1 was less effective (Figure 4a ). As expected, there was no effect from the E6/E7-Intron siRNA, as it targets the fulllength transcript and most E7 is translated from the spliced transcript. The effects of E7 silencing on Rb protein levels were examined by western blot using an anti-pRb antibody. The level of the active hypophosphorylated form of Rb increased after treatment with E6/E7-Ex2 siRNA consistent with decreased E7 (Figure 4b ).
Reduction in cellular proliferation after short interfering RNA treatment
Having shown that downregulation of E6 and E7 after siRNA treatment restored p53 and hypophosphorylated Rb protein levels, we assessed their effects on cell proliferation. Introduction of E6/E7-Intron or E6/E7-Ex2 siRNA led to a small but significant reduction in CaSki cell growth over 5 days (Figure 5a ). There was a greater effect in SiHa cells, E6/E7-Ex2 siRNA treatment being more effective than E6/E7-Intron siRNA, leading to a 22% reduction in proliferation, indicating that targeting both E6 and E7 is more effective for growth arrest. The greatest reduction in cellular proliferation was achieved when the two siRNAs were combined, presumably because the E6/E7-Intron siRNA is more effective at silencing E6 expression than E6/E7-Ex2, and E6/E7-Ex2 is also required to silence E7. There was no loss of proliferation in HPV-negative C33-A cells.
To determine whether restored p53 and hypophosphoylated Rb functions affected the rate of apoptosis, cells were analyzed by annexin V staining after siRNA treatment. In CaSki cells, E6/E7-Intron siRNA caused 35% of cells to stain positive for the apoptosis marker (Figure 5b) , however, fewer cells showed evidence of apoptosis when E6/E7-Ex2 siRNA was used. As the reduction in CaSki cellular proliferation was the same regardless of whether intronic or exonic siRNA was used, this would suggest that the elevation of p53 without pRb favors apoptosis, and rescue of both regulatory proteins favors cellular senescence. In SiHa cells, the results were different as E6/E7-Intron siRNA resulted in much less apoptosis, exonic siRNA having the greater effect. However, combined E6/E7-Intron and E6/E7-Ex2 siRNA treatment led to the greatest levels of apoptosis, consistent with the cellular proliferation data. There was no apoptosis mediated by the introduction of siRNA in the HPV-negative C33-A cells.
Synergistic or additive effects with chemotherapy agents
As the effects of siRNAs alone on cellular proliferation were limited, we tested whether there was any potential synergy with various chemotherapy agents. The treatment of the cervical cell lines with six cytotoxic agents, namely, paclitaxel, cisplatin, carboplatin, irinotecan, leptomycin B and doxorubicin, resulted in dose-dependent toxicity (paclitaxel, leptomycin B and doxorubicin effective at nanomolar concentrations; cisplatin, carboplatin and irinotecan effective at micromolar concentrations), CaSki cells being more sensitive than SiHa cells in each case (data not shown). Each drug was then combined with intronic or exonic E6/E7 siRNA, to determine whether damage induced by the cytotoxic agent would synergise with the removal of suppression of pocket proteins and p53. Both types of siRNA with paclitaxel led to additive toxicity in SiHa cells, however, in CaSki cells, dual treatment resulted in a synergistic cell killing (Figure 6a ). For example, in CaSki cells treated with 3 nM paclitaxel, viability fell from 50% in the absence of siRNA to 15% with 30 nM E6/E7-Intron siRNA, the curve falling to the left of the dotted line representing the theoretical additive toxicity. Using E6/E7-Ex2 siRNA with paclitaxel, the degree of cytotoxicity was also synergistic, but less than was achieved using E6/E7-Intron siRNA. As expected, NS siRNA had no effect in either cell line.
In contrast, cells treated with siRNA and cisplatin or carboplatin showed evidence of sub-additive toxicity, shown by the combined curve moving to the right of drug alone, most notably with E6/E7-Ex2 siRNA (Figures 6b  and c) . CaSki cells treated with either irinotecan, leptomycin B or doxorubicin in combination with siRNA exhibited additive toxicities in each case (Figures 6d-f) .
Efficacy of combined short interfering RNA/ chemotherapy treatment on subcutaneous cervical tumors Finally we examined the effect of siRNA treatment and chemotherapy on human xenografts grown subcutaneously in nude mice. On the basis of the in vitro data the most effective siRNA combination occurred with paclitaxel in CaSki cells; however, the implantation of CaSki cells into MF1 nude mice resulted in a low take rate for tumors. We therefore tested combination therapy using a SiHa xenograft model that grew more reproducibly. Treatment consisted of two doses of paclitaxel, given intravenously 4 days apart, and two doses of siRNA, administered by intratumoral injection at the same times. As expected, there was a clear difference manifested in both the rate of tumor growth and survival, between mock-treated animals and those receiving paclitaxel alone (Figure 7) . However, the co-administration of non-specific siRNA and paclitaxel reduced the tumor inhibitory effect, resulting in decreased survival. The reason for this is unclear, but as the non-specific siRNA seemed to reduce paclitaxel efficacy in SiHa cells in vitro, it likely reflects a property of the siRNA specifically or non-specifically downregulating products required for paclitaxel-mediated cell death. Co-delivery of exonic (E6/E7-Ex2) siRNA with paclitaxel showed no Reduction in E7 protein after the delivery of E7 targeting short interfering RNA (siRNA) leading to increased levels of underphosphorylated Rb. (a) CaSki-cell extracts were analyzed by western blotting using an HPV16 E7 monoclonal antibody at 24 h after delivery of 100 nM intronic or exonic E6/E7 siRNA, or control siRNA targeting luciferase. (b) pRb levels were examined at 44 h after siRNA delivery using an anti-Rb antibody. The purified mouse anti-human retinoblastoma protein antibody binds to the hyperphosphorylated (ppRB) (inactive) and underphosphorylated (pRb) (active) forms of the protein. Samples were analyzed for a-tubulin to ensure equivalent sample loading in each case.
tumor-suppressive benefit over non-specific siRNA, again showing antagonism of the effect of paclitaxel alone. In contrast, co-administration of both exonic (E6/E7-Ex2) and intronic (E6/E7-Intron) siRNA with paclitaxel restored the tumor-suppressive effect and extended survival to the levels observed with paclitaxel alone (Figure 7 ). This would suggest that downregulation of E6 is more effective than E7 when combined with paclitaxel for therapeutic efficacy.
Discussion
Cervical carcinoma is unusual among human cancers, in that the p53 and Rb genes are rarely mutated. 20, 42, 43 Instead, disruption of the cell cycle is attributable to the combined effects of the high-risk human papillomaviruses. As a result, several studies have focussed on the strategies against the viral oncogene products, as this allows discrimination between target and non-target cells. [44] [45] [46] Despite the successful studies using RNA interference (RNAi) to downregulate HPV16 and HPV18 E6 and E7, the effects on cell growth or the amount of apoptosis have been limited. 32, 33, 35 We have observed similar results, effectively downregulating viral gene expression, but having relatively minor effects on cell growth. The delivery of siRNA targeting E6/E7 introns to cervical cancer cells containing HPV16 sequences led to an 80% loss of full-length transcripts, and thus E6 mRNA, and a corresponding rise in nuclear accumulation of p53, findings consistent with Jiang and Milner, 32 Butz et al. 34 and Tang et al. 39 This resulted in modest effects on growth arrest, with a greater degree of apoptosis in CaSki cells compared with SiHa cells. It is therefore apparent that siRNA monotherapies are unlikely to be clinically successful, despite improvements to siRNA design 47 and improved understanding of the HPV E6/E7 splicing pattern.
To enhance cytotoxic responses because of the restored p53/pRb activity, some groups have attempted to induce cellular stress with chemotherapy agents. It is hoped that combined chemotherapy and RNAi will induce synergistic toxicity, reducing the concentration at which the chemotherapy drug is effective, and thus reducing local and systemic toxicity. 36, 37, 48 Koivusalo et al. 36 examined the effect of ten chemotherapy agents on HPV18-positive HeLa cells treated with intronic E6/E7 siRNA. The combined cytotoxic effect of E6 siRNA and chemotherapy ranged from subadditive to synergistic depending on the drug. Cisplatin and carboplatin are DNA alkylating agents that work by crosslinking DNA, thus interfering with cell division. Koivusalo et al. reported that concurrent treatment of cisplatin and siRNA targeting full-length HPV18 E6/E7 transcripts (but not spliced transcripts) resulted in subadditive toxicity in HeLa cells. 36 In contrast, Putral et al. 37 reported that a short hairpin RNA expressing siRNAs that target both spliced and full-length HPV16 E6/E7 transcripts increased the sensitivity of CaSki cells to cisplatin. However, siRNAs not expressed from hairpins did not significantly increase CaSki cell sensitivity. They attributed the difference to longer-term expression of siRNAs from the hairpin construct. Our results using siRNAs in their final form, in agreement with Koivusalo et al. suggest that targeting both HPV16 E6 and E7 reduced the efficacy of cisplatin treatment.
In contrast, the treatment of cells with paclitaxel and siRNA led to synergistic toxicity in agreement with the study by Koivusalo et al. Paclitaxel, developed from the bark of the Pacific yew tree, is a mitotic inhibitor, which functions by binding to the b subunit of tubulin preventing microtubule disassembly during cell division. However, at concentrations lower than those that affect tubulin polymerization, all anti-microtubule drugs suppress mitotic microtubules leading to mitotic arrest and cell death. 49 Gianakakou et al. showed that low dose (6 nM) paclitaxel led to a higher induction of p21 in A549 cells than A549 cells expressing HPV E6, which suppressed p53. 50 This would suggest that E6 partially prevented paclitaxel-induced p53 and p21 activity, which was accountable for the greater G1 arrest observed in A549 than A549-E6 cells. Therefore, G1 arrest caused by low concentration of paclitaxel is dependent on p53 induction. Progression of the cell cycle is driven by activation of cyclin-dependent kinases (CDKs) in response to intraand extra-cellular signals. Cells are committed to division after phosphorylation of Rb protein during mid to late G1 phase. CDK inhibitors decelerate the cell cycle by inactivating CDKs that phosphorylate the Rb protein.
Schmidt and Fan showed that treatment of A431 human vulvar epidermoid carcinoma cells containing functional Rb, with ecdysone-induced CKI expression, conferred resistance to paclitaxel-mediated toxicity. 51 Although in SiHa cells with defective Rb protein, the induction of CKI expression did not affect sensitivity to paclitaxel. As HPV E7 interacts with CKIs, p21 WAF1/CIP1 and p27
KIP1
, as well as Rb, it is possible that downregulation of E7 would increase phosphorylated Rb and CKIs and increase resistance to paclitaxel. Indeed, exonic siRNA (targeting both E6 and E7) and paclitaxel were less effective than intronic siRNA (targeting E6) alone with paclitaxel for CaSki cell cytotoxicity in vitro (Figure 6a) , and combined intronic and exonic siRNA with paclitaxel (against SiHa cells) in vivo (Figure 7) . We therefore propose that future developments of siRNA as a chemosensitising agent for paclitaxel treatment of cervical cancer should focus predominantly on the suppression of E6 alone, using intronic siRNA targets.
Paclitaxel, like many chemotherapy agents, can induce toxic side effects in patients, including low white blood cell counts, weakness, pain in joints and muscles, peripheral neuropathy or tingling, nausea and vomiting and occasionally death. The identification of siRNA synergy could therefore allow a decrease in the chemotherapy agent dose, reducing unwanted toxicity, provided efficient siRNA delivery routes can be established. Efforts have suggested that topical administration of siRNA to cervical tissue 52 may be possible for localized disease, however, systemic delivery mechanisms will be required for advanced metastatic disease.
An unexpected antagonism was observed between intratumoral delivery of non-specific siRNA and intravenous paclitaxel, leading to decreased anticancer activity compared with paclitaxel alone. This effect was strong and reproducible and was even reflected in oligofectamine studies in vitro. The reason for this is unclear, however, it is possible that the non-specific siRNA has RNAi activity against genes involved in paclitaxel-mediated cell death. Chemical modifications to the siRNA such as 2 0 -O-Me in the seed sequence are known to reduce off-target effects (reviewed in 53 ), and we envisage any potential therapeutic agent to be suitably modified. Alternatively, the sense strand on the non-specific siRNA contains a GUGU motif, which could be immunostimulatory, 54, 55 again interfering with the mechanism of paclitaxel-mediated cell death. The use of non-targeting siRNAs as controls for RNAi requires caution given the potential for sequence-dependent side effects and interferon induction.
In summary, for RNAi monotherapy the most effective reduction in cell proliferation occurred by targeting both E6 and E7, using exonic or combined intronic and exonic E6/E7 siRNA. However, to improve cell killing to any therapeutically meaningful level, combination with chemotherapy was required. When paclitaxel was combined with siRNA, the use of intronic siRNA targeting full-length transcripts only, and thus degrading E6 and restoring p53, resulted in the greatest level of cytotoxicity. Tumor growth and survival in SiHa xenografts after intravenous administration of paclitaxel and intratumor administration of short interfering RNA (siRNA). Female MF1 nude mice of 6-8-week-old were subcutaneously implanted with 3.2 Â 10 6 SiHa cells and randomized into five groups (n ¼ 4 or 5) of mock, paclitaxel only, paclitaxel þ siNS, paclitaxel þ E6/E7-Ex2 siRNA or paclitaxel þ E6/E7-Intron þ E6/E7-Ex2. On day 1 and 4, the mice received 10 mg kg -1 paclitaxel or vehicle intravenously, and 2 mg siRNA or vehicle intramorally. Tumor volume was measured every 2-3 days until tumors reached 905 mm 3 when mice were euthanized.
